VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Stock Information for VYNE Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VYNE Therapeutics Inc.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement 
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.